PROCYTOX TAB 50MG 50 MG
CYCLOPHOSPHAMIDE : 50 MG · DIN 02241796 · BAXTER CORPORATION
Health Canada status: MARKETED
What is PROCYTOX TAB 50MG?
PROCYTOX TAB 50MG 50 MG contains CYCLOPHOSPHAMIDE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02241796, held by BAXTER CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 09-Sep-2003. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PROCYTOX TAB 50MG used for?
Malignant lymphomas (Hodgkin's, NHL), multiple myeloma, leukemias (CLL, CML, AML, ALL), mycosis fungoides, neuroblastoma, adenocarcinoma of the breast, retinoblastoma, and lung neoplasms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02241796 |
|---|---|
| Brand name | PROCYTOX TAB 50MG |
| Generic / active ingredient | CYCLOPHOSPHAMIDE : 50 MG |
| Manufacturer | BAXTER CORPORATION |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01AA01 CYCLOPHOSPHAMIDE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Sep-2003 |
| Original market date | 2000-08-22 00:00:00 |
How is it administered?
Oral or IV. Dosage must be individualized based on clinical/hematologic response. Use only under supervision of physicians experienced in cancer chemotherapy. Hydration and mesna recommended.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C (implied by standard USP/Product Monograph conventions, though specific range text was truncated in snippet).
How is it supplied?
Tablets: 25 mg, 50 mg. Injection: 200 mg, 500 mg, 1000 mg, 2000 mg per vial.
Contraindications
Hypersensitivity; urinary outflow obstruction; severe myelosuppression, renal or hepatic impairment; active infection (especially varicella zoster); severe immunosuppression.
Warnings and precautions
Potent antineoplastic; secondary malignancies; severe myelosuppression; urotoxicity (hemorrhagic cystitis); cardiotoxicity; pulmonary toxicity; anaphylaxis; interferes with wound healing.
Is CYCLOPHOSPHAMIDE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by ANDONE PHARMACEUTICAL INC (Tier 3 shortage CYCLOPHOSPHAMIDE FOR INJECTION USP" aria-label="Anticipated Tier 3 shortage CYCLOPHOSPHAMIDE FOR INJECTI), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01AA01 CYCLOPHOSPHAMIDE. 12 of 28 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 1000 MG | Injection | STERIMAX INC | MARKETED | DIN 02547686 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 1000 MG | POWDER FOR SOLUTION | ANDONE PHARMACEUTICAL INC | MARKETED | DIN 02546736 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 1000 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02560216 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 2000 MG | POWDER FOR SOLUTION | ANDONE PHARMACEUTICAL INC | MARKETED | DIN 02546744 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 2000 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02560224 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 2000 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02547694 |
| PROCYTOX | 1000 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02241799 |
| PROCYTOX | 200 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02241797 |
| PROCYTOX | 2000 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02241800 |
| PROCYTOX | 500 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02241798 |
Who else supplies CYCLOPHOSPHAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CYCLOPHOSPHAMIDE appears in 28 registered pack listings across 5 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.